NextCell to present at the INNODIA Symposium during EASD 2026

NextCell Pharma AB (“NextCell” or the “Company”) announces that the Phase II clinical trial evaluating ProTrans® (allogeneic Wharton’s Jelly-derived mesenchymal stromal cells) for respiratory complications associated with COVID-19 has been accepted for publication in Cytotherapy (https://www.isct-cytotherapy.org/article/S1465-3249(26)00736-X/abstract), the official journal of the International Society for Cell & Gene Therapy.

At the Extraordinary General Meeting of NextCell Pharma AB (publ) (“NextCell” or the “Company”) held on 21 August 2025, it was resolved that the Company shall change its financial year from a broken financial year September–August to a calendar year January–December. The Company’s first full financial year in accordance with the calendar year will be 2026. To facilitate historical comparisons and enhance transparency for future reports that will follow the calendar year structure, the Company is today publishing financial information for the five most recent comparative quarters.

NextCell Pharma AB (publ) (“NextCell” or the “Company”) publishes its Year-End Report for the extended financial year September 1, 2024 – December 31, 2025. The report is available on the company´s website: www.nextcellpharma.com. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period last year for the fourth quarter (October-December 2024) and twelve months (the previous fiscal year September 2023 - August 2024).

NextCell Pharma AB (“NextCell” or the “Company”) announces its participation in the Japan Entry Acceleration Program (“JEAP”) in regenerative medicine, an international accelerator initiative organized and funded by JETRO. NextCell is communicating its participation in connection with the Company’s current presence in Tokyo, where program activities and meetings with Japanese industrial, regulatory and financial stakeholders are now taking place.

NextCell Pharma AB (“NextCell” or the “Company”) today announces long-term follow-up data from the ProTrans-Repeat study showing sustained preservation of endogenous insulin production in patients with newly diagnosed type 1 diabetes. The data extends to approximately 6 years after the last ProTrans infusion, corresponding to 7 to 7.5 years since the first infusion.

NextCell Pharma AB (“NextCell” or the “Company”) provides a strategic update on its focused market progression strategy, aimed at accelerating value creation by advancing ProTrans™ in adult patients, where NextCell already has a strong clinical foundation, while simultaneously strengthening the company’s global partnering position. This approach builds on NextCell’s original development strategy and is designed to create multiple independent value drivers for the company.

The shareholders of NextCell Pharma AB (publ), reg. no. 556965-8361, (the "Company") are hereby invited to attend an extraordinary general meeting on Tuesday, 10th of February 2026, at 10:00 CET at Novum-huset, floor 6 (lift E), Hälsovägen 7, Huddinge. Registration for the meeting will commence at 09.30 CET.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE, HONG KONG, JAPAN, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” AT THE END OF THE PRESS RELEASE. The Board of Directors of NextCell Pharma AB (“NextCell” or the “Company”) has resolved to propose to the extraordinary general meeting (the “Extraordinary General Meeting”) to resolve on a directed share issue comprising a total of 15,000,000 shares to a number of strategic investors at a subscription price of SEK 1.00 per share (the “Directed Issue”). Participating investors include both new investors and a number of larger existing shareholders. The Extraordinary General Meeting is planned to be held on Tuesday, 10 February 2026. Notice of the Extraordinary General Meeting will be announced separately.